Agency Forms Undergoing Paperwork Reduction Act Review, 35165-35166 [2014-14331]
Download as PDF
<![CDATA[
35165
Federal Register / Vol. 79, No. 118 / Thursday, June 19, 2014 / Notices
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. Written comments should
be received within 60 days of this
notice.
Proposed Project
National Survey of Primary Care
Policies for Managing Patients with
High Blood Pressure, High Cholesterol,
or Diabetes—New—National Center for
Health Statistics (NCHS), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Cardiovascular disease is a leading
cause of death and disability for men
and women in the United States, among
the most costly health problems facing
our nation today, and among the most
preventable. Risk factors for
cardiovascular disease include high
blood pressure and high cholesterol.
Because over 50% of diabetics have
high blood pressure, high cholesterol, or
both conditions, the optimal systems to
treat people with hypertension, high
cholesterol, or diabetes are interrelated.
In 2005, CDC’s Division for Heart
Disease and Stroke Prevention (DHDSP)
began developing evaluation indicators
that reflect evidence-based outcomes
use of evidence-based systems,
including multidisciplinary team
approaches for chronic disease
treatment, electronic health records
(EHR) with features appropriate for
treating patients with chronic disease
(e.g., clinical decision supports, patient
registries), and patient follow-up
mechanisms. Approximately 945
physicians will participate in the data
collection. This is a one-time data
collection.
Information will be used to examine
health systems and dissemination of
health systems technology. Results will
be used by primary care practices to
inform their systems for managing
patients with chronic conditions and to
improve the quality of care delivered.
Results will be used by NCHS and CDC
to improve technical assistance to
public health partners.
Because this project was previously
submitted by the CDC’s National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), a 60-day
notice was previously published by
NCCDPHP on April 29, 2011 (Vol. 76,
No. 83, pp. 24029–24030).
OMB approval is requested for three
years. Participation in the Survey is
voluntary and all responses will be deidentified. There are no costs to
respondents other than their time. The
total estimated annualized burden hours
are 287.
from policy, systems, and
environmental changes related to heart
disease and stroke prevention. However,
many of the indicators for short-term
policy and systems changes do not have
readily available data sources. This is
particularly true for outcomes related to
health care systems changes.
NCHS proposes to conduct a new
information collection, the National
Survey of Primary Care Policies for
Managing Patients with High Blood
Pressure, High Cholesterol, or Diabetes.
This survey will serve as an extension
of the National Ambulatory Medical
Care Survey (NAMCS) (OMB No. 0920–
0234), NCHS’s primary survey on officebased physicians. In order to minimize
the burden on physicians currently
sampled in NAMCS, this survey is being
launched as a distinct data-collection
effort, but will use NAMCS definitions,
questions, and specifications as
appropriate. The survey will be targeted
to primary care physicians specializing
in internal medicine or family practice.
Respondents will be drawn from a
nationally representative sample of
physicians. Physicians working in
hospitals, federal facilities, nursing
homes, rehabilitation centers and
correctional facilities will not be eligible
for the survey. Eligibility will be
determined by phone. The survey
instrument will undergo cognitive
testing before administration.
The mail-based survey will collect
information about physician practices’
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Type of respondent
Form name
Physician ...........................................
Physician ...........................................
Medical Secretary .............................
Physician ...........................................
Cognitive Testing Screener ..............
Cognitive Testing Protocol ...............
NSPCP Screener .............................
NSPCP .............................................
10
10
1,000
315
1
1
1
1
10/60
75/60
10/60
20/60
2
13
167
105
Total ...........................................
...........................................................
........................
........................
........................
287
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–14359 Filed 6–18–14; 8:45 am]
[30Day–14–0905]
BILLING CODE 4163–18–P
emcdonald on DSK67QTVN1PROD with NOTICES
Leroy Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Agency Forms Undergoing Paperwork
Reduction Act Review
Centers for Disease Control and
Prevention
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
VerDate Mar<15>2010
17:25 Jun 18, 2014
Jkt 232001
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
E:\FR\FM\19JNN1.SGM
19JNN1
35166
Federal Register / Vol. 79, No. 118 / Thursday, June 19, 2014 / Notices
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
FoodNet Non-O157 Shiga ToxinProducing E. coli Study: Assessment of
Risk Factors for Laboratory-Confirmed
Infections and Characterization of
Illnesses by Microbiological
Characteristics (OMB No. 0920–0905,
expires 11/30/14)—Extension—National
Center for Emerging and Zoonotic
Infectious Diseases, Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Each year many Shiga toxinproducing E. coli (STEC) infections
occur in the United States, ranging in
severity from mild diarrhea, to
hemorrhagic colitis and in some cases,
life-threatening hemolytic uremic
syndrome (HUS). HUS occurs most
frequently following infection with
serogroup O157; 6% of patients with
this type of STEC infection develop
HUS, with highest occurrence in
children aged <5 years. HUS has a
fatality rate of approximately 5%; up to
25% of HUS survivors are left with
chronic kidney damage.
STEC are broadly categorized into two
groups by their O antigens, STEC O157
and non-O157 STEC. The serogroup
O157 is most frequently isolated and
most strongly associated with HUS. Risk
factors for STEC O157 infections in the
United States and internationally have
been intensely studied. Non-O157 STEC
is a diverse group that includes all Shiga
toxin-producing E. coli of serogroups
other than O157. Over 50 STEC
serogroups are known to have caused
human illness. Numerous non-O157
outbreaks have been reported from
throughout the world and clinical
outcomes in some patients can be as
severe as those seen with STEC O157
infections, however, little is known
about the specific risk factors for
infections due to non-O157 STEC
serogroups. More comprehensive
understanding of risk factors for
sporadic non-O157 STEC infections is
needed to inform prevention and
control efforts.
The FoodNet case-control study is the
first multistate investigation of nonoutbreak-associated non-O157 STEC
infections in the United States. It
investigates risk factors for non-O157
STEC infections, both as a group and
individually for the most common nonO157 STEC serogroups. In addition, the
study characterizes the major known
virulence factors of non-O157 STEC to
assess how risk factors and clinical
features vary by virulence factor
profiles. As the largest, most
comprehensive, and most powerful
study of its kind, it is making an
important contribution towards better
understanding of non-O157 STEC
infections and will provide sciencebased recommendations for
interventions to prevent these
infections.
Study enrollment began between July
and September 2012 (sites had staggered
start dates) and is scheduled to run for
36 months. Since we have not yet
enrolled enough cases to meet the study
objectives, we are requesting an
extension.
Persons with non-O157 STEC
infections who are identified as part of
routine public health surveillance and
randomly selected healthy persons in
the patients’ communities (to serve as
controls) are contacted and offered
enrollment into this study. Participation
is completely voluntary and there is no
cost for enrollment. The estimated
annual burden is 268 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Patients ...........................................................
Controls ...........................................................
Case questionnaire ........................................
Control questionnaire .....................................
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–14331 Filed 6–18–14; 8:45 am]
[60Day–14–0666]
BILLING CODE 4163–18–P
emcdonald on DSK67QTVN1PROD with NOTICES
Leroy Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Proposed Data Collections Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention
The Centers for Disease Control and
Prevention (CDC), as part of its
continuing effort to reduce public
burden, invites the general public and
other Federal agencies to take this
opportunity to comment on proposed
VerDate Mar<15>2010
17:25 Jun 18, 2014
Jkt 232001
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
161
483
Number of
responses per
respondent
1
1
Average
burden per
response
(in hrs.)
25/60
25/60
and/or continuing information
collections, as required by the
Paperwork Reduction Act of 1995. To
request more information on the below
proposed project or to obtain a copy of
the information collection plan and
instruments, call 404–639–7570 or send
comments to Leroy Richardson, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments submitted in response to
this notice will be summarized and/or
included in the request for Office of
Management and Budget (OMB)
approval. Comments are invited on: (a)
Whether the proposed collection of
information is necessary for the proper
E:\FR\FM\19JNN1.SGM
19JNN1
]]>Agencies
[Federal Register Volume 79, Number 118 (Thursday, June 19, 2014)]
[Notices]
[Pages 35165-35166]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-14331]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-14-0905]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
[[Page 35166]]
burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (c) Enhance the
quality, utility, and clarity of the information to be collected; (d)
Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses; and (e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
FoodNet Non-O157 Shiga Toxin-Producing E. coli Study: Assessment of
Risk Factors for Laboratory-Confirmed Infections and Characterization
of Illnesses by Microbiological Characteristics (OMB No. 0920-0905,
expires 11/30/14)--Extension--National Center for Emerging and Zoonotic
Infectious Diseases, Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Each year many Shiga toxin-producing E. coli (STEC) infections
occur in the United States, ranging in severity from mild diarrhea, to
hemorrhagic colitis and in some cases, life-threatening hemolytic
uremic syndrome (HUS). HUS occurs most frequently following infection
with serogroup O157; 6% of patients with this type of STEC infection
develop HUS, with highest occurrence in children aged <5 years. HUS has
a fatality rate of approximately 5%; up to 25% of HUS survivors are
left with chronic kidney damage.
STEC are broadly categorized into two groups by their O antigens,
STEC O157 and non-O157 STEC. The serogroup O157 is most frequently
isolated and most strongly associated with HUS. Risk factors for STEC
O157 infections in the United States and internationally have been
intensely studied. Non-O157 STEC is a diverse group that includes all
Shiga toxin-producing E. coli of serogroups other than O157. Over 50
STEC serogroups are known to have caused human illness. Numerous non-
O157 outbreaks have been reported from throughout the world and
clinical outcomes in some patients can be as severe as those seen with
STEC O157 infections, however, little is known about the specific risk
factors for infections due to non-O157 STEC serogroups. More
comprehensive understanding of risk factors for sporadic non-O157 STEC
infections is needed to inform prevention and control efforts.
The FoodNet case-control study is the first multistate
investigation of non-outbreak-associated non-O157 STEC infections in
the United States. It investigates risk factors for non-O157 STEC
infections, both as a group and individually for the most common non-
O157 STEC serogroups. In addition, the study characterizes the major
known virulence factors of non-O157 STEC to assess how risk factors and
clinical features vary by virulence factor profiles. As the largest,
most comprehensive, and most powerful study of its kind, it is making
an important contribution towards better understanding of non-O157 STEC
infections and will provide science-based recommendations for
interventions to prevent these infections.
Study enrollment began between July and September 2012 (sites had
staggered start dates) and is scheduled to run for 36 months. Since we
have not yet enrolled enough cases to meet the study objectives, we are
requesting an extension.
Persons with non-O157 STEC infections who are identified as part of
routine public health surveillance and randomly selected healthy
persons in the patients' communities (to serve as controls) are
contacted and offered enrollment into this study. Participation is
completely voluntary and there is no cost for enrollment. The estimated
annual burden is 268 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hrs.)
----------------------------------------------------------------------------------------------------------------
Patients.............................. Case questionnaire...... 161 1 25/60
Controls.............................. Control questionnaire... 483 1 25/60
----------------------------------------------------------------------------------------------------------------
Leroy Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-14331 Filed 6-18-14; 8:45 am]
BILLING CODE 4163-18-P
